FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2328163089> ?p ?o ?g. }

• W2328163089 endingPage "361" @default.
• W2328163089 startingPage "347" @default.
• W2328163089 abstract "c-Src is a tyrosine kinase belonging to the Src-family kinases. It is overexpressed and/or hyperactivated in a variety of cancer cells, thus its inhibition has been predicted to have therapeutic effects in solid tumors. Recently, the pyrazolo[3,4-d]pyrimidine 3 was reported as a dual c-Src/Abl inhibitor. Herein we describe a multidisciplinary drug discovery approach for the optimization of the lead 3 against c-Src. Starting from the X-ray crystal structure of c-Src in complex with 3, Monte Carlo free energy perturbation calculations were applied to guide the design of c-Src inhibitors with improved activities. As a result, the introduction of a meta hydroxyl group on the C4 anilino ring was computed to be particularly favorable. The potency of the synthesized inhibitors was increased with respect to the starting lead 3. The best identified compounds were also found active in the inhibition of neuroblastoma cell proliferation. Furthermore, compound 29 also showed in vivo activity in xenograft model using SH-SY5Y cells." @default.
• W2328163089 created "2016-06-24" @default.
• W2328163089 creator A5001780639 @default.
• W2328163089 creator A5002876711 @default.
• W2328163089 creator A5008783082 @default.
• W2328163089 creator A5010109904 @default.
• W2328163089 creator A5016372629 @default.
• W2328163089 creator A5016735563 @default.
• W2328163089 creator A5017335504 @default.
• W2328163089 creator A5046402166 @default.
• W2328163089 creator A5053144466 @default.
• W2328163089 creator A5056135019 @default.
• W2328163089 creator A5056536140 @default.
• W2328163089 creator A5068650467 @default.
• W2328163089 creator A5068941229 @default.
• W2328163089 creator A5071830380 @default.
• W2328163089 creator A5090204935 @default.
• W2328163089 creator A5090835353 @default.
• W2328163089 creator A5091202892 @default.
• W2328163089 date "2014-12-03" @default.
• W2328163089 modified "2023-10-16" @default.
• W2328163089 title "Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-<i>d</i>]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma" @default.
• W2328163089 cites W1974903851 @default.
• W2328163089 cites W1976248779 @default.
• W2328163089 cites W1978434376 @default.
• W2328163089 cites W1985510130 @default.
• W2328163089 cites W1986191025 @default.
• W2328163089 cites W1990161102 @default.
• W2328163089 cites W1990524359 @default.
• W2328163089 cites W1993453850 @default.
• W2328163089 cites W1995017064 @default.
• W2328163089 cites W2000840258 @default.
• W2328163089 cites W2013908731 @default.
• W2328163089 cites W2020254298 @default.
• W2328163089 cites W2024262880 @default.
• W2328163089 cites W2024951966 @default.
• W2328163089 cites W2027633770 @default.
• W2328163089 cites W2028841370 @default.
• W2328163089 cites W2038772546 @default.
• W2328163089 cites W2038840577 @default.
• W2328163089 cites W2038940604 @default.
• W2328163089 cites W2046107124 @default.
• W2328163089 cites W2048633418 @default.
• W2328163089 cites W2050328092 @default.
• W2328163089 cites W2056516302 @default.
• W2328163089 cites W2057610072 @default.
• W2328163089 cites W2059955037 @default.
• W2328163089 cites W2063350668 @default.
• W2328163089 cites W2063779505 @default.
• W2328163089 cites W2067191435 @default.
• W2328163089 cites W2067606868 @default.
• W2328163089 cites W2067699471 @default.
• W2328163089 cites W2071051270 @default.
• W2328163089 cites W2072802467 @default.
• W2328163089 cites W2073101936 @default.
• W2328163089 cites W2077384736 @default.
• W2328163089 cites W2087146932 @default.
• W2328163089 cites W2088179569 @default.
• W2328163089 cites W2092748268 @default.
• W2328163089 cites W2093379071 @default.
• W2328163089 cites W2094545147 @default.
• W2328163089 cites W2114367386 @default.
• W2328163089 cites W2118139320 @default.
• W2328163089 cites W2129153475 @default.
• W2328163089 cites W2129707387 @default.
• W2328163089 cites W2138216545 @default.
• W2328163089 cites W2144081223 @default.
• W2328163089 cites W2146860018 @default.
• W2328163089 cites W2146928870 @default.
• W2328163089 cites W2151676798 @default.
• W2328163089 cites W2160695434 @default.
• W2328163089 cites W2163239556 @default.
• W2328163089 cites W2166546141 @default.
• W2328163089 cites W2316506824 @default.
• W2328163089 cites W2327522594 @default.
• W2328163089 cites W2334727267 @default.
• W2328163089 cites W4211031423 @default.
• W2328163089 doi "https://doi.org/10.1021/jm5013159" @default.
• W2328163089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25469771" @default.
• W2328163089 hasPublicationYear "2014" @default.
• W2328163089 type Work @default.
• W2328163089 sameAs 2328163089 @default.
• W2328163089 citedByCount "48" @default.
• W2328163089 countsByYear W23281630892015 @default.
• W2328163089 countsByYear W23281630892016 @default.
• W2328163089 countsByYear W23281630892017 @default.
• W2328163089 countsByYear W23281630892018 @default.
• W2328163089 countsByYear W23281630892019 @default.
• W2328163089 countsByYear W23281630892020 @default.
• W2328163089 countsByYear W23281630892021 @default.
• W2328163089 countsByYear W23281630892022 @default.
• W2328163089 countsByYear W23281630892023 @default.
• W2328163089 crossrefType "journal-article" @default.
• W2328163089 hasAuthorship W2328163089A5001780639 @default.
• W2328163089 hasAuthorship W2328163089A5002876711 @default.
• W2328163089 hasAuthorship W2328163089A5008783082 @default.
• W2328163089 hasAuthorship W2328163089A5010109904 @default.
• W2328163089 hasAuthorship W2328163089A5016372629 @default.

• next